louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05740826: Correlation Between Cervical Spine Muscle Disorders and the Occurrence of Symptoms of Temporomandibular Joint Dysfunction
Official title: Correlation Between Cervical Spine Muscle Disorders and the Occurrence of Symptoms of Temporomandibular Joint Dysfunction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Temporomandibular Joint Disorders
Keywords: TMJ disorders
pressure sensitivity
algometer
young adults
myofascial pain
Lead sponsor: Poznan University of Medical Sciences
Sponsor class: OTHER
First posted: 2023-02-23
Enrollment: 60
Sex: ALL
Minimum age (years): 19
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Students from Poland

Brief summary: This study evaluated the correlation between the occurrence of disorders of selected muscles of the cervical spine and the occurrence of symptoms of TMJ dysfunction

Detailed description: The examination includes personal questionnaire, physical examination and an algometer measurement on the upper fibers of the trapezius, levator scapula, sternocleidomastoid and rectus capitis posterior major to define pressure sensitivity of neck muscles and define is there a correlation between the occurrence of disorders of selected muscles of the cervical spine and the occurrence of symptoms of TMJ dysfunction.

Eligibility criteria: Inclusion Criteria:

* age 19-25 years
* relatively good health
* consent to participate in the research experiment

Exclusion Criteria:

* people with skin problems in the head and neck area that that made the examination impossible
* previous head and neck surgeries and traffic injuries
* coagulation disorders or taking medications that reduce blood coagulability
* venous thrombosis in the neck area
* sensory disorders
* dislocation of the jaw in the past
* taking painkillers 12 hours before starting the study
* being under orthodontic or physiotherapeutic treatment focused on TMJ dysfunctions

Primary outcomes:
measure: Pressure sensitivity
timeFrame: for each participant duration of test is about 30-40 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Poznań
country: Poland
facility: Clinic for Rehabilitation
state: Wielkopolskie
Study officials:
References:
Clinical trial NCT03984526: Atropine or Ephedrine Pretreatment for Preventing Bradycardia in Elderly Patients
Official title: Comparison of Effect of Atropine or Ephedrine Pretreatment for Preventing Bradycardia Under Sedation With Dexmedetomidine After Spinal Anesthesia in Elderly Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Anesthesia, Spinal
Dexmedetomidine
Bradycardia
Lead sponsor: Ajou University School of Medicine
Sponsor class: OTHER
First posted: 2019-06-13
Enrollment: 102
Sex: ALL
Minimum age (years): 65
Maximum age (years): 100
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Spinal anesthesia is widely used for lower extremity surgery, and sedation is often required during surgery. For sedation, propofol, midazolam and dexmedetomidine are frequently used. Dexmedetomidine is a highly selective alpha 2 receptor agonist, and has sedating and analgesic effect. Compared with propofol and midazolam, it has little or no respiratory inhibition and hemodynamically stable. It also has the effect of reducing delirium in the elderly. Dexmedetomidine has also been reported to prolong the duration of sensory and motor blockade effects of spinal anesthesia. However, several studies have reported that administration of dexmedetomidine in spinal anesthesia increases the incidence of bradycardia.

In a study of healthy young adults, concurrent administration of atropine with dexmedetomidine in spinal anesthesia significantly reduced the frequency of bradycardia requiring treatment. However, in elderly patients, it is often reported that there is little response to atropine in bradycardia, and ephedrine is more effective in treating bradycardia than atropine in the elderly.

The investigators therefore compared ephedrine and atropine as pretreatment to reduce the incidence of bradycardia when using dexmedetomidine as a sedative in elderly patients undergoing spinal anesthesia.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists (ASA) classification I-II
* Undergoing orthopedic surgery under spinal anesthesia

Exclusion Criteria:

* Contraindication for spinal anesthesia
* Atrial fibrillation, atrial flutter
* Cardiac valve disease
* Neurologic disease
* initial systolic blood pressure in operating room \> 160mmHg

Primary outcomes:
measure: The incidence of intervention for bradycardia
timeFrame: for 1 hour after spinal anesthesia
Secondary outcomes:
measure: The incidence of intervention for hypotension
timeFrame: for 1 hour after spinal anesthesia
measure: Systolic/ mean/ diastolic blood pressure
timeFrame: for 1 hour after spinal anesthesia
Other outcomes:
Locations:
city: Suwon-si
country: Korea, Republic of
facility: Ajou universitiy school of medicine
state: Gyeong-gi Do
Study officials:
affiliation: Ajou University School of Medicine
name: yun jeong chae, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05358665: The Effects of Long-Term Mask Use in the Pandemic Period
Official title: An Investigation of Temporomandibular Pain, Headache, and Fatigue in Relation With Long-Term Mask Use During the Pandemics
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Keywords: mask
temporomandibular joint disorders
headache
fatigue
Lead sponsor: Ankara Yildirim Beyazıt University
Sponsor class: OTHER
First posted: 2022-05-03
Enrollment: 909
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People using masks

Brief summary: Various restrictions have been made all over the world due to coronavirus pandemics. In addition to situations such as social isolation and hygiene, the use of masks is among these rules. In addition to the protection it provides, the use of masks causes some negative situations in individuals. For this reason, the aim of our study is to examine the effects of long-term mask use on temporomandibular dysfunction, headache and fatigue.


Eligibility criteria: Inclusion Criteria:

* Over 18 years
* Able to read and understand
* Volunteer to participate

Exclusion Criteria:

* Malignity history
* Head/Face surgery history

Primary outcomes:
measure: Temporomandibular Dysfunction
timeFrame: Baseline
Secondary outcomes:
measure: Mask Use Symptoms
timeFrame: Baseline
measure: Perceptions of Mask Use
timeFrame: Baseline
measure: Fatigue
timeFrame: Baseline
measure: Type of Headache
timeFrame: Baseline
measure: Trigger point of temporomandibular joint
timeFrame: Baseline
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara Yildirim Beyazit University
Study officials:
References:
Clinical trial NCT04702165: Image - Navigated Resection of Lung Nodules
Official title: Image - Navigated Resection of Lung Nodules
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Lung Diseases
Keywords: lung nodule
lung cancer
lung mass
Lead sponsor: Navigation Sciences, Inc.
Sponsor class: INDUSTRY
First posted: 2021-01-08
Enrollment: 25
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: This is an open label study lung nodules that are either cancer or non-cancer and who are eligible for surgical resection. Patients will undergo their surgery with the help of the Lung Resection Marker Locator Kit which will assist the surgeon in both the location and resection of the lung nodule under real-time guidance.


Eligibility criteria: Inclusion Criteria:

1. Males or females aged 21 years or older as it is extremely rare for younger people to be at risk for lung cancers.
2. Be deemed candidates for the lung resection surgery, which will be determined by their treating Thoracic Surgeon (also a physician investigator)
3. Have lesions that are nodules/GGO or other abnormal opacity that can be accurately measured in at least one dimension using conventional techniques
4. Seen at BWH Thoracic Surgery outpatient clinics or as inpatient (Note: Subjects will be formally consented to the study at BWH only)

Exclusion Criteria:

1. Female subjects pregnant or breastfeeding
2. Subjects with a pacemaker or equivalent devices (AICD) due to the use of electromagnetic tracking generator.
3. Patients who are not scheduled for lung surgery

   -

Primary outcomes:
measure: To compare the measurements from the J-bar fiducial to the first staple line obtained by the device in vivo to that performed in the frozen section room on the lung specimen obtained (which includes both the J bar and the staple line).
timeFrame: 1 day
Secondary outcomes:
measure: whether coefficient is needed
timeFrame: 1 day
measure: time required for device placement
timeFrame: 1 day
measure: demonstrate safe surgical remove of lung nodule
timeFrame: 30 day
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
References:
Clinical trial NCT03642665: Natural Versus Artificial Cycle for Frozen-Thawed Embryo Transfer
Official title: Frozen-thawed Embryo Transfer in a Natural Versus Artificial Cycle: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Embryo Transfer
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
Collaborators: name: GZA Ziekenhuizen Campus Sint-Augustinus
name: Imelda Hospital, Bonheiden
name: Jessa Hospital
First posted: 2018-08-22
Enrollment: 554
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Multicenter prospective randomized clinical trial
Primary purpose: TREATMENT

Brief summary: This study evaluates clinical pregnancy rates, obstetrical outcome parameters, costs and patient preferences in natural cycle versus artificial cycle frozen embryo transfers (FET).

Detailed description: Transfer of cryopreserved embryos can be performed in a natural cycle (NC-FET) or in an artificially prepared cycle (AC-FET). Both cycle regimens have their advantages and disadvantages. So far, most comparative studies have failed to identify the optimal protocol for FET. In this study patients undergoing FET will be randomized between an endometrial preparation by a natural cycle or by an artificial cycle (by oestradiol validate and micronized progesterone).

Eligibility criteria: Inclusion Criteria:

* Women undergoing FET after a first, second or third fresh IVF/ICSI cycle
* Single embryo transfer (SET) or Double embryo transfer (DET)
* Female age between 18-45 year
* Women having a natural ovulatory cycle (24-35 days)
* Normal uterine cavity (fundal indentation at the cavity \<10mm)
* Written informed consent

Exclusion Criteria:

* Use of donor gametes
* BMI \> or equal to 35 kg / m2
* Any contra-indication to estrogen or progesterone supplementation (e.g. history of thrombosis, prior or current hormone-sensitive malignancy...)

Primary outcomes:
measure: Clinical pregnancy rate with fetal heart beat
timeFrame: 9 weeks
Secondary outcomes:
measure: Biochemical pregnancy rate
timeFrame: 9 weeks
measure: Miscarriage rate
timeFrame: 12 weeks
measure: Ectopic pregnancy rate
timeFrame: 9 weeks
measure: Live birth rate
timeFrame: 41 weeks
measure: Multiple pregnancy rate
timeFrame: 9 weeks
measure: Adverse events
timeFrame: 12 weeks
measure: Cycle cancellation rate
timeFrame: 4 weeks
measure: Endometrial thickness
timeFrame: 3 weeks
measure: Endometrial pattern
timeFrame: 3 weeks
measure: number of center visits to monitor FET cycle
timeFrame: From date of randomization until the date of the embryo transfer or until cancellation (estimated period of time up to 4 weeks)
measure: cost analysis per treatment cycle
timeFrame: From date of randomization until the date of the embryo transfer or until cancellation (estimated period of time up to 4 weeks)
measure: patient satisfaction
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: UZ Leuven
Study officials:
References:
Clinical trial NCT00997165: Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort
Official title: Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Metabolic Diseases
Sleep Apnea
Atherosclerosis
Keywords: fatty liver
adipose tissue
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2009-10-19
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any patient suspected of metabolic syndrome with or without sleep apnea or liver steatosis.

Informed consent with signature.

Brief summary: The NUMEVOX cohort is intended to follow-up the macro and microvascular dysfunction in relation to adipose tissue repartition in patients with metabolic syndrome associated to liver steatosis, sleep apnea. Duration of the follow-up is 3 years for each patient entering the cohort.


Eligibility criteria: Inclusion Criteria:

* informed consent
* age \> 18 years old
* suspected of metabolic syndrome
* affiliated to french social health care

Exclusion Criteria:

* age \< 18 years old
* pregnancy
* no informed consent
* not eligible for the study (no MS, cancer)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Angers
country: France
facility: Pôle Maladies Métaboliques et Médecine Interne
Study officials:
affiliation: UH Angers
name: pierre henri Ducluzeau, MD PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05060965: Inpatient Smoking Cessation Pilot Program
Official title: Smoking Cessation Pilot Program on 9 South
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: EARLY_PHASE1
Conditions: Tobacco Use Cessation
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2021-09-29
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The investigators are implementing a stepwise approach to cessation with a public health focus to improve health outcomes for the investigators' pediatric patients. The investigators are focusing on addressing caregiver smoking as a modifiable risk factor during time of child's hospitalization as a window of opportunity to provide counseling and education to families on secondhand and third hand smoke exposure as well as information on NRT products to heighten caregiver contemplation for quitting. One of the central goals of the investigators' project is to increase immediate access to Nicotine Replacement Therapy (NRT) resources for families during hospitalization which pediatric providers could potentially dose and prescribe to caregivers who are screened positive for smoking. Long-term cessation care is provided by referrals to both the MD Quitline and the John Hopkins Tobacco Treatment Clinic. Both are provided to allow participants options that the participants would find preferable from an insurance and provider perspective.


Eligibility criteria: Inclusion Criteria:

* Caregivers of patients on an inpatient unit at Johns Hopkins Children's Center who self-identify as tobacco users and wish to initiate tobacco cessation

Exclusion Criteria:

* Pregnant or breast feeding maternal caregivers.

Primary outcomes:
measure: Change in Self-reported attempts to quit smoking
timeFrame: Baseline, 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months
Secondary outcomes:
measure: Change in Frequency of usage of outpatient tobacco cessation services
timeFrame: Baseline, 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months
measure: Change in Usage of nicotine replacement therapy products
timeFrame: Baseline, 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins Hospital
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Mandeep S. Jassal, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04707365: Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort
Official title: Interactions Between Tumor, Tumor Microenvironment and Immune System in Digestive Cancers : Impact on Survival and Response to Treatment
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Colorectal Cancer
Pancreas Tumor
Biliary Tract Tumor
Immune System and Related Disorders
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2021-01-13
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Retrospective and prospective monocentric cohort study
Primary purpose: PREVENTION

Brief summary: Colorectal and pancreatobiliary cancers are the most common digestive cancers. Their incidence has particularly increased over the last few decades, leading to suspicion that environmental factors are involved. In addition, strategies for the therapeutic management of these cancers are evolving in the context of the development of immunotherapies.

Tumor microenvironment is a potential source of new diagnostic, prognostic and predictive markers and new therapeutic targets. The links between tumor microenvironment and modulation of the immune system in colorectal and pancreatobiliary cancers are poorly understood. Molecular classifications have been proposed for these cancers, but their link with immunity and response to treatment remains to be explored.

Objective : explore links between molecular subtypes, tumor microenvironment, host (immune system, pre-metastatic niche, intestinal microbiota, metabolism), and survival (prognostic value), response (predictive value) and tolerance (toxicities) to treatments in digestive cancers, in particular colorectal and pancreatobiliary cancers.

Method: Retrospective and prospective monocentric cohort study


Eligibility criteria: Inclusion Criteria:

* Colorectal or pancreatic adenocarcinoma or biliary tract adenocarcinoma
* Cytologically or histologically proven adenocarcinoma, regardless of stage and treatment
* Age ≥ 18 years old
* Diagnosed from 2015 onwards
* Signed Consent
* Affiliation to a social security scheme (including CMU (Universal health coverage))

Exclusion Criteria:

* Patient under guardianship, curatorship or safeguarding of justice
* Pregnant or breastfeeding woman
* Any medical, psychological or social situation that could prevent compliance with the protocol according to the investigator's assessment.
* Refusal to participate in the study
* Patient on AME (state medical assistance)
* Persons deprived of liberty by a judicial or administrative decision
* Persons under psychiatric care

Primary outcomes:
measure: overall survival
timeFrame: observation from first cancer treatment date until date of death or 10 years follow up if patient alive
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: AP-HP Henri Mondor Créteil
name: Pr Tournigand
role: STUDY_DIRECTOR
References:
Clinical trial NCT06563765: FAP-targeting PET/CT for Noninvasive Monitoring of Renal Fibrosis
Official title: FAP-targeting PET/CT for Noninvasive Monitoring of Renal Fibrosis
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: CKD
Renal Fibrosis
Keywords: CKD
Renal fibrosis
FAP
Lead sponsor: Peking University First Hospital
Sponsor class: OTHER
First posted: 2024-08-21
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Chronic kidney disease (CKD) is an irreversible change of kidney function and structure caused by many reasons. The main threat of CKD to human health is progressive renal function decline. Delaying the progression of chronic kidney disease to end-stage renal failure is an important clinical need, and renal fibrosis is a common pathway for the progression of chronic kidney disease to end-stage renal failure. The evaluation of renal fibrosis is of great value for the course and prognosis of patients with chronic kidney disease. However, pathological detection has the disadvantages of trauma, false negative, and cannot be implemented repeatedly. At present, there is a lack of effective non-invasive, dynamic, real-time monitoring and evaluation means. A commercially available FAP-targeted imaging agent, FAPI-04, has been used for PET/CT imaging of systemic fibrosis lesions with high uptake background in normal kidneys. Although it can show severe renal fibrosis, it is not conducive to the detection rate of patients with mild-moderate fibrosis who need more accurate evaluation. The new targeted FAP imaging agent successfully constructed by our research group has proved that it can show the degree of renal fibrosis at the living level and has correlation. Therefore, this study intends to carry out a series of clinical studies on the imaging of renal fibrosis with new targeted FAP probes, evaluate the specificity and sensitivity of the new targeted FAP probes in the diagnosis of renal fibrosis, and ultimately provide a new method for clinical dynamic, non-invasive assessment and monitoring of the degree and progression of renal fibrosis.


Eligibility criteria: Inclusion Criteria:

* Patients with chronic kidney disease
* Renal pathology was performed within 2 weeks

Exclusion Criteria:

* Pregnant or lactating patients

Primary outcomes:
measure: Pathological type
timeFrame: 1 week after enrollment
measure: Pathological MESTC score
timeFrame: 1 week after enrollment
measure: serum creatinine (μmol/L)
timeFrame: 1 month before enrollment and 1 month after enrollment
measure: 24-hour urinary protein (g/24h)
timeFrame: 1 month before enrollment and 1 month after enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University First Hospital
state: Beijing
Study officials:
References: